Total Payments
$1.2M
2024 Payments
$136,147
Companies
38
Transactions
2,044
Medicare Patients
10,668
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$899,142 (72.0%)
Consulting$197,653 (15.8%)
Travel$88,733 (7.1%)
Food & Beverage$39,449 (3.2%)
Research$22,800 (1.8%)
Education$654.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $864,742 | 361 | 69.3% |
| Consulting Fee | $197,653 | 91 | 15.8% |
| Travel and Lodging | $88,733 | 255 | 7.1% |
| Food and Beverage | $39,449 | 1,300 | 3.2% |
| Honoraria | $34,400 | 13 | 2.8% |
| Unspecified | $22,800 | 11 | 1.8% |
| Education | $654.62 | 13 | 0.1% |
Payments by Type
General
$1.2M
2,033 transactions
Research
$22,800
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $326,397 | 351 | $0 (2024) |
| Lilly USA, LLC | $151,577 | 204 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $112,678 | 87 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $109,189 | 92 | $0 (2024) |
| Janssen Biotech, Inc. | $93,704 | 534 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $66,346 | 72 | $0 (2024) |
| Celgene Corporation | $64,072 | 86 | $0 (2019) |
| Amgen Inc. | $53,609 | 87 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $52,407 | 90 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $47,548 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $136,147 | 227 | UCB, Inc. ($25,394) |
| 2023 | $209,252 | 288 | E.R. Squibb & Sons, L.L.C. ($67,489) |
| 2022 | $94,218 | 143 | E.R. Squibb & Sons, L.L.C. ($22,857) |
| 2021 | $71,931 | 121 | AbbVie Inc. ($27,662) |
| 2020 | $84,795 | 118 | AbbVie Inc. ($29,639) |
| 2019 | $207,624 | 345 | AbbVie, Inc. ($81,218) |
| 2018 | $226,309 | 409 | AbbVie, Inc. ($63,836) |
| 2017 | $218,154 | 393 | AbbVie, Inc. ($67,895) |
All Payment Transactions
2,044 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Dermatology | ||||||
| 12/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.25 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,135.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.43 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $548.57 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $88.97 | General |
| Category: Immunology | ||||||
| 12/06/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $478.39 | General |
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $26.51 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $43.08 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $120.06 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $7,456 | 3 |
| H13-147 | AbbVie, Inc. | $4,200 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $3,348 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $239.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 3,059 | 16,430 | $2.3M | $1.3M |
| 2022 | 16 | 2,733 | 13,519 | $1.7M | $1.0M |
| 2021 | 18 | 2,695 | 11,219 | $1.4M | $801,926 |
| 2020 | 17 | 2,181 | 9,300 | $1.2M | $711,323 |
Total Patients
10,668
Total Services
50,468
Medicare Billing
$3.8M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 30 | 9,700 | $1.4M | $1.1M | 77.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 814 | 1,154 | $294,979 | $79,387 | 26.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 558 | 788 | $159,642 | $36,927 | 23.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 290 | 366 | $122,612 | $34,575 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 191 | 286 | $97,955 | $28,738 | 29.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 185 | 217 | $61,590 | $18,863 | 30.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 443 | 3,040 | $72,960 | $17,825 | 24.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 106 | 130 | $22,125 | $5,838 | 26.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 54 | 54 | $17,060 | $4,152 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 41 | 48 | $18,291 | $3,787 | 20.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 61 | 69 | $18,580 | $3,441 | 18.5% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 18 | 22 | $11,800 | $3,252 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,400 | $2,862 | 30.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 38 | 51 | $7,038 | $2,311 | 32.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 38 | 48 | $14,866 | $1,939 | 13.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2023 | 23 | 23 | $9,177 | $1,356 | 14.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 39 | 112 | $4,032 | $1,336 | 33.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 21 | 21 | $4,650 | $1,162 | 25.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 13 | 23 | $3,940 | $1,026 | 26.0% |
| 69100 | Biopsy of ear | Office | 2023 | 13 | 14 | $3,360 | $1,015 | 30.2% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 16 | 18 | $5,829 | $339.92 | 5.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 32 | 198 | $4,017 | $325.16 | 8.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 25 | $75.00 | $20.77 | 27.7% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2022 | 21 | 7,100 | $994,000 | $769,910 | 77.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 720 | 1,049 | $157,350 | $71,094 | 45.2% |
About Dr. Jeffrey Sobell, MD
Dr. Jeffrey Sobell, MD is a Dermatology healthcare provider based in Chestnut Hill, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154383610.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Sobell, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $136,147 received in 2024. These payments were reported across 2,044 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($864,742).
As a Medicare-enrolled provider, Sobell has provided services to 10,668 Medicare beneficiaries, totaling 50,468 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Chestnut Hill, MA
- Active Since 04/03/2006
- Last Updated 05/30/2012
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1154383610
Products in Payments
- TALTZ (Drug) $148,141
- Humira (Biological) $128,382
- TREMFYA (Drug) $109,145
- SKYRIZI (Biological) $99,216
- Otezla (Drug) $94,963
- Sotyktu (Drug) $77,259
- Tremfya (Drug) $61,254
- DUPIXENT (Biological) $54,470
- COSENTYX (Biological) $52,005
- VTAMA (Drug) $33,110
- ILUMYA (Biological) $33,000
- DUPIXENT DUPILUMAB INJECTION (Biological) $31,596
- Bimzelx (Biological) $25,428
- STELARA (Biological) $24,710
- Skyrizi (Biological) $12,985
- DUPIXENT (Drug) $8,581
- Zoryve (Drug) $8,458
- ILUMYA (tildrakizumab-asmn) injection (Biological) $8,283
- Ilumya (Biological) $6,132
- ATOPIC DERMATITIS - DISEASE (Drug) $4,809
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Chestnut Hill
Michael Kaminer, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Jeffrey Dover, Md, MD
Dermatology — Payments: $241,174
Dermatology $241,174
Kenneth Arndt, Md, MD
Dermatology — Payments: $38,802
Dermatology $38,802
Dr. Brooke Sikora, M.d, M.D
Dermatology — Payments: $26,039
Dermatology $26,039
Thomas Rohrer, M.d, M.D
Dermatology — Payments: $12,331
Dermatology $12,331
Robin Travers, Md, MD
Dermatology — Payments: $7,746
Dermatology $7,746